Antony A. Riley - 21 Nov 2024 Form 4 Insider Report for Forte Biosciences, Inc. (FBRX)

Role: CHIEF FINANCIAL OFFICER
Signature: /s/ Paul A. Wagner, Ph.D., as Attorney-in-Fact
Issuer symbol: FBRX
Transactions as of: 21 Nov 2024
Net transactions value: +$124,998
Form type: 4
Filing time: 22 Nov 2024, 17:45:42 UTC
Previous filing: 02 Oct 2024
Next filing: 02 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	FBRX	Common Stock	Purchase	$124,998	+22,514	+273%	$5.55	30,776	21 Nov 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On November 19, 2024, the Issuer and the Reporting Person entered into a Securities Purchase Agreement (the "SPA"), pursuant to which the Reporting Person purchased 22,514 shares of common stock from the Issuer in a private placement in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended. The transaction contemplated by the SPA closed on November 21, 2024.

Content

On November 19, 2024, the Issuer and the Reporting Person entered into a Securities Purchase Agreement (the "SPA"), pursuant to which the Reporting Person purchased 22,514 shares of common stock from the Issuer in a private placement in reliance upon the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933, as amended. The transaction contemplated by the SPA closed on November 21, 2024.